Why Trazodone May Lose Its Effect Over Time—and What to Do About It

You've been taking trazodone for eighteen months. Sleep came more easily, your mood stabilized, and life began to feel manageable again. Then, gradually, things shifted. The medication that once worked reliably now seems to offer less. You're sleeping fewer hours, or waking more often, or noticing that the emotional steadiness you'd come to count on has quietly eroded. You haven't changed your dose. Nothing obvious in your life has changed either.

This experience—often described by patients as the medication "wearing off"—is real, and it deserves a clinical explanation rather than dismissal. Understanding what is actually happening at a pharmacological and physiological level is the first step toward making an informed decision about next steps.

Defining the Problem: Tolerance vs. Tachyphylaxis vs. Relapse

Before any clinical response can be formulated, it helps to be precise about terminology, because different explanations call for different interventions.

Pharmacological tolerance refers to a reduction in drug effect that results from the body's adaptive response to sustained exposure. The nervous system, faced with a persistent pharmacological signal, compensates by adjusting receptor density, sensitivity, or downstream signaling pathways. Over time, the same dose produces a diminished response.

Tachyphylaxis is a related but distinct concept—it describes a rapid or sudden loss of response, sometimes occurring within days or weeks rather than months. In antidepressant therapy, the term is sometimes used loosely to describe what is more accurately called antidepressant poop-out, a colloquial but widely recognized phenomenon in which a previously effective antidepressant gradually loses efficacy without any obvious external trigger.

Relapse or disease progression, by contrast, is not a drug phenomenon at all—it reflects the natural course of the underlying condition. Depression, anxiety disorders, and chronic insomnia are not static states. They fluctuate over time, and a patient whose condition worsens may incorrectly attribute that worsening to the medication failing rather than the illness evolving.

Distinguishing between these possibilities matters enormously, because the appropriate clinical response differs for each.

Is Trazodone Particularly Prone to Tolerance?

Trazodone occupies an unusual position in psychopharmacology. It is used both as a primary antidepressant and—far more commonly in contemporary US practice—as an off-label sleep aid. Tolerance patterns may differ depending on which indication is driving its use.

For sleep-related use, there is meaningful evidence that the sedating effects of trazodone can diminish over time. The mechanism likely involves adaptive changes at histamine H1 and alpha-1 adrenergic receptors, both of which contribute to trazodone's sedation. Patients who initially fell asleep within thirty minutes of taking 50 mg may find, after several months, that the same dose no longer reliably induces sleep. This is a recognized clinical phenomenon, though it is less well-characterized in the published literature than tolerance to benzodiazepines or Z-drugs.

For antidepressant use, the picture is more complex. Trazodone's serotonergic mechanisms—including reuptake inhibition and 5-HT2A receptor antagonism—are subject to receptor downregulation with chronic exposure, a process that occurs with virtually all serotonergic agents. Whether this translates into clinically meaningful loss of antidepressant effect at standard doses is not definitively established, but clinical experience and case series suggest it does occur in a subset of patients.

Other Explanations Worth Ruling Out First

Before concluding that trazodone itself has become less effective, clinicians and patients should consider several alternative explanations:

• Life stressors: Major changes in work, relationships, finances, or health can overwhelm a medication's buffering capacity. The drug hasn't changed; the clinical burden has increased.
• Sleep hygiene deterioration: Patients who improved their sleep behaviors alongside starting trazodone may have gradually abandoned those practices, reducing the medication's apparent effectiveness.
• Medication interactions: New prescriptions, over-the-counter medications, or supplements may be interfering with trazodone's metabolism or competing pharmacodynamically.
• Adherence changes: Irregular dosing, timing shifts, or taking the medication with food versus without can alter absorption and plasma levels.
• Substance use: Increased alcohol consumption, in particular, can disrupt sleep architecture in ways that counteract trazodone's benefits.

A thorough medication review and honest conversation about lifestyle factors should precede any pharmacological adjustment.

Strategies for Responding to Treatment Plateau

When tolerance or tachyphylaxis appears to be the most plausible explanation after other factors are excluded, several evidence-informed strategies are available.

Dose Optimization

For some patients, a modest dose increase restores clinical benefit. If a patient has been stable on 150 mg for antidepressant purposes, a supervised increase to 200 or 250 mg may re-establish adequate plasma levels relative to their current receptor sensitivity. This strategy carries the advantage of simplicity but the limitation of a ceiling—trazodone has a maximum recommended dose, and escalation is not indefinitely sustainable.

For sleep use, however, dose escalation should be approached carefully. Higher doses increase the risk of next-day sedation, orthostatic hypotension, and—in rare cases—priapism. The risk-benefit calculation shifts at doses above 150 mg for purely hypnotic purposes.

Drug Holidays and Cycling

Some clinicians advocate for planned brief interruptions in trazodone therapy to allow receptor resensitization, particularly for patients using it as a sleep aid. The evidence base for this approach is limited, and it carries the risk of rebound insomnia or mood destabilization. If pursued, it should be done under close clinical supervision and never abruptly in patients using trazodone for major depressive disorder.

Augmentation Strategies

For patients experiencing antidepressant poop-out on trazodone as their primary mood medication, augmentation with a complementary agent may restore response. Common augmentation partners in US clinical practice include low-dose atypical antipsychotics (such as aripiprazole or quetiapine), lithium, or thyroid hormone supplementation—each with its own evidence base and risk profile. These decisions require careful individualization.

For sleep-specific plateau, behavioral interventions—particularly Cognitive Behavioral Therapy for Insomnia (CBT-I)—have strong evidence and are recommended by the American College of Physicians as a first-line treatment. CBT-I can be layered onto pharmacotherapy or used to facilitate a gradual taper.

Switching Medications

When dose optimization and augmentation fail to restore adequate benefit, transitioning to a different agent becomes the evidence-based choice. For depression, this might mean moving to an SSRI, SNRI, or bupropion, depending on the patient's symptom profile and prior medication history. For insomnia, options include low-dose doxepin (FDA-approved specifically for sleep maintenance), suvorexant, or lemborexant—agents with distinct mechanisms that may bypass the tolerance pathways that have developed to trazodone.

The transition process requires careful planning to avoid discontinuation symptoms and to ensure continuity of therapeutic benefit during the crossover period.

Having the Conversation With Your Provider

If you suspect trazodone is no longer working as well as it once did, the most important step is to raise this concern explicitly with your prescribing clinician—and to do so before the situation becomes a crisis. Bring specific observations: when the change began, how it manifests, whether anything in your life or routine has shifted. The more concrete your account, the more effectively your provider can distinguish between tolerance, relapse, and circumstantial factors.

Treatment plateau is not a failure—it is a clinical signal that deserves a thoughtful, individualized response. The goal of antidepressant therapy has always been sustained improvement in function and well-being, and reaching that goal sometimes requires adjusting course.